Preimplantation Genetic Testing for Monogenic/Single Gene Defects (PGT-M) is a type of genetic testing done during in vitro fertilization (IVF) treatment. This test identifies specific genetic conditions, allowing the fertility specialist to choose the healthiest embryos, increasing the chance of a successful pregnancy and a healthy baby.
It is a means of avoiding transmission of a specific genetic disorder without a couple having the possibility of the baby being affected and therefore having to face the decision of terminating the pregnancy.
PGT-M can decrease the risk of miscarriage and this technology can help you achieve a healthy pregnancy. Individuals who suspect or know they carry genes for serious medical conditions may opt to screen for healthy embryos ahead of time. PGT-M can test for over 400 different disorders such as cystic fibrosis, sickle cell anemia, Huntington’s disease, or other hereditary conditions.
Preimplantation Genetic Testing for Monogenic/Single Gene Defects (PGT-M) is a more enhanced process than Preimplantation Genetic Testing for Aneuplodity (PGT-A) since it scans for individual genes.
Following the first steps of an IVF procedure (retrieving the eggs and fertilizing the eggs in a lab to create embryos), the lab team will remove 5 to 7 cells from an embryo that is 5 days old. The embryos can be frozen for future transfer as soon as the biopsy is done. These cells are then sent to a genetics lab for evaluation.
The PGT-M test will take 1 – 2 weeks to generate results.
